Core Viewpoint - The company, Fuhong Hanlin (02696), has received approval from the National Medical Products Administration for clinical trials of a combination therapy involving HLX43, HLX07, and Surulitinib for the treatment of advanced solid tumors, leading to a stock price increase of over 4% in early trading [1]. Group 1: Company Developments - Fuhong Hanlin's stock price rose by 3.48% to HKD 56.5, with a trading volume of HKD 12.65 million [1]. - The company plans to conduct Phase II clinical research for the combination therapy in China once conditions are met [1]. Group 2: Product Information - HLX43 is a novel DNA topoisomerase I inhibitor conjugated with a PD-L1 targeting antibody, developed for treating advanced/metastatic solid tumors [1]. - HLX07 is an innovative biopharmaceutical developed by Fuhong Hanlin targeting the EGFR for advanced solid tumors [1]. - Surulitinib is an innovative anti-PD-1 monoclonal antibody developed by Fuhong Hanlin [1].
港股异动 | 复宏汉霖(02696)早盘涨超4% HLX43联合疗法获国家药监局批准开展临床试验